Abstract
Focusing on biotechnology firms, this study analyzes the relationship between the level of intensity of the research and development (R&D) conducted by a firm, the debt financing decisions the firm makes, and the overall value of the firm. The data presented shows that, although most firms are unlikely to acquire financing from the debt market, the opposite is true for firms in the biotechnology industry. One reason for this divergence may be the belief among biotechnology firms that their future commercial success depends on their ability to develop new products, resulting in a strategy of intense R&D. Furthermore, an examination of firm values reveals that while most firm values are negatively correlated with leverage and R&D intensity, biotechnology firm values show no such correlation, implying that biotechnology firms prioritize sustainable commercial success no matter the source of financing.
Subject
Management, Monitoring, Policy and Law,Renewable Energy, Sustainability and the Environment,Geography, Planning and Development
Reference63 articles.
1. Scale and Scope: The Dynamics of Industrial Capitalism;Chandler,1994
2. The Strategy-Focused Organization: How Balanced Scorecard Companies Thrive in the New Business Environment;Kaplan,2001
3. Performance implications of strategic performance measurement in financial services firms
4. Post-approval R D raises total drug development costs to $897 million;Tufts;Impact Rep.,2013
5. An Evolutionary Theory of Economic Change;Nelson,1982
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献